Why Is AngioDynamics (ANGO) Stock Down -21.85% Today?
Key Takeaways
- Shares plunged roughly 21.85% in Wednesday's session, sliding from a prior close of $14.19 to around $11.09.
- Primary catalyst: The company's fiscal Q1 2027 earnings release, which beat headline estimates but failed to ease concerns about profitability and growth quality.
- Secondary driver: An unexpected leadership change, with longtime CEO Jim Clemmer retiring and Eric Honroth set to take over effective November 2.
- Guidance in focus: Management reiterated an adjusted full-year loss outlook and projected flat sales in its legacy Med Device segment.
- Broader context: The selloff accelerated intraday, extending a decline that has pressured the stock in recent weeks.
- What to watch next: Leadership transition details, Med Tech momentum, and any progress toward profitability.
Opening Summary
AngioDynamics, Inc. (ANGO) is a medical technology company that designs and sells minimally invasive devices for vascular access, peripheral vascular disease, and oncology procedures, with a portfolio headlined by the Auryon atherectomy system, thrombectomy platforms, and the NanoKnife ablation technology. Shares tumbled about 21.85% on Wednesday, falling from a prior close of $14.19 to roughly $11.09 in intraday trading. The decline came even though the company reported fiscal first-quarter results that modestly beat analyst estimates, as investors focused instead on continued losses, flat guidance for part of the business, and a surprise CEO succession announcement.
Earnings Results and Guidance
For its fiscal 2027 first quarter, ANGO posted an adjusted loss of $0.04 per share, narrower than the $0.11 loss analysts had expected, while revenue of $80.9 million edged past the roughly $80.5 million consensus and rose 6.9% year over year. The Med Tech segment grew 13.2% to $39.9 million, marking an eighth consecutive quarter of double-digit growth, while the Med Device segment generated $41.0 million, up 1.4%. Gross margin expanded 410 basis points to 59.4%, though that figure benefited from tariff refunds received during the quarter.
Despite the top-line beat, the market reaction was sharply negative. The company remains unprofitable on a GAAP basis, reporting a net loss of $7.1 million, or $0.17 per share. Management reiterated full-year guidance calling for adjusted EPS of negative $0.29 to negative $0.24 and revenue of $336 million to $341 million, with adjusted EBITDA of $13 million to $16 million. Investors appeared to weigh the reiterated adjusted loss and a projection of flat Med Device net sales growth against an elevated valuation, prompting the earnings-driven selloff.
Leadership Transition Weighs on Sentiment
Compounding the earnings reaction, ANGO announced that President and CEO Jim Clemmer will retire after ten years at the helm, with Eric Honroth named as his successor effective November 2. While succession of this kind is often routine, the timing of the disclosure alongside quarterly results added an element of execution uncertainty. In the press release, Clemmer emphasized confidence in the fiscal 2027 outlook and pledged to remain closely involved to ensure a smooth transition, but the leadership change nonetheless contributed to the negative sentiment that drove shares lower through the session.
Market Context and Trading Activity
The decline in ANGO unfolded with meaningful selling pressure, reflecting a stock that had already been volatile in recent weeks. The move pushed the shares well below recent short-term trading levels and back toward the lower end of the range established over the past several months. The selloff in this mid-cap medical device name was driven primarily by company-specific news rather than a broad sector move, as investors reacted to the combination of continued losses, restrained growth in the legacy device business, tariff-related headwinds, and the incoming executive change. Trading volume in the name has historically been modest, and the concentrated intraday decline suggests an outsized re-rating of the shares relative to their recent range.
What Comes Next for ANGO
Looking ahead, investors will monitor how the leadership transition unfolds and whether the incoming CEO signals any shift in strategy or capital-allocation priorities. Attention will also remain on the Med Tech segment, which management expects to grow 12% to 15% for fiscal 2027, and on whether tariff impacts continue to pressure margins at levels "broadly similar" to the prior year. Risks include the company's persistent unprofitability, uncertain tariff conditions, and the possibility that Med Device sales remain flat. A sustained path toward profitability and continued double-digit Med Tech momentum will be central to any stabilization in the share price.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots to see which automated strategies are currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANGO in downward trend: 10-day moving average broke below 50-day moving average on October 05, 2026
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 66 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ANGO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 201 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 126 of 179 cases where ANGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ANGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.826) is normal, around the industry mean (5.020). P/E Ratio (44.843) is within average values for comparable stocks, (166.342). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther
Advertisement